Pharmacogenetics of etanercept in rheumatoid arthritis.
Pharmacogenetics of etanercept in rheumatoid arthritis.
复制标题
DOI：
10.2217/14622416.9.8.1011
复制
发表时间：
2008-08
期刊：
影响因子：
2.1
通讯作者：
Bridges SL
中科院分区：
文献类型：
--
作者：
Danila MI;Hughes LB;Bridges SL
依那西普是被批准用于类风湿性关节炎（RA）和多种其他免疫介导的炎症性疾病的几种TNF抑制剂之一。鉴于批准用于类风湿关节炎的药物过多，以及成本和治疗反应的广泛差异，疗效标志物将非常有用。已经检查了几个候选基因，包括HLA-DRB 1等位基因和编码TNF、TNF受体和Fc受体的基因，以确定其在依那西普治疗应答中的作用。在这篇综述中，我们讨论了依那西普在RA和其他疾病中的药物遗传学研究，并对此类分析的未来进行了评论，以推进RA个性化医疗的目标。
Etanercept is one of several TNF inhibitors approved for rheumatoid arthritis (RA) and a variety of other immune-mediated inflammatory conditions. Given the plethora of drugs approved for RA and the wide variations in cost and treatment response, markers of efficacy would be very useful. Several candidate genes, including HLA-DRB1 alleles and those encoding TNF, TNF receptors, and Fc receptors, have been examined for a role in the response to treatment with etanercept. In this review, we discuss pharmacogenetic studies of etanercept in RA and other diseases, and comment on the future of such analyses to advance the goal of personalized medicine in RA.